Last updated: May 29, 2026
Belbuca (buprenorphine) is an FDA-approved opioid analgesic supplied for the U.S. market as an oral buccal film. U.S. supply chain visibility is driven by (1) FDA drug labeling and establishment listings and (2) Orange Book and agency drug master file (DMF) references used by NDA holders. Belbuca’s commercial supply is controlled by its NDA holder’s approved manufacturing and packaging network, with product-specific control over site, process, and packaging configuration via FDA-approved manufacturing supplements and DMFs.
Key practical supplier frame: treat “supplier” as (a) the NDA holder’s labeled manufacturer and packager sites for Belbuca film strength(s), (b) contract manufacturers (CMOs) disclosed via FDA establishment records tied to those sites, and (c) DMF-linked raw material and film component suppliers.
What companies are suppliers for BELBUCA buprenorphine buccal film in the U.S.?
Answer: Belbuca’s labeled manufacturing and packaging supply chain is determined by the NDA holder’s FDA-approved product manufacturing sites listed in FDA labeling/establishment records for the dosage form and strength. Those sites can include CMOs for film fabrication, finishing, and packaging, but public “supplier” identifications must be mapped to named FDA manufacturing/packaging establishments for the specific dosage form.
Who is the NDA holder and product owner for BELBUCA?
Belbuca is marketed in the U.S. under NDA ownership associated with Helsinn Therapeutics (U.S.) / Endo commercial branding and distribution history. Supply chain contracting for film production and packaging is controlled under that NDA’s manufacturing network and supplements.
Which manufacturers and packagers supply BELBUCA film strengths?
Belbuca is sold in multiple strengths (microgram ranges). The practical supplier set is the set of FDA-approved manufacturing and packaging establishments for each strength. Those establishments can differ across strengths if packaging configuration or film manufacturing process is separately validated.
What to extract for a supplier map (high-relevance deliverables):
- Labeled manufacturer sites for “Belbuca (buprenorphine) buccal film” by strength.
- Labeled packager sites (primary packaging, secondary cartons, lot packaging).
- Any testing or releasing sites (if listed separately in labeling/establishment entries).
- Whether any sites are CMOs (commonly shown via the establishment’s name in FDA records even when the NDA holder is the label owner).
How do I identify BELBUCA suppliers from the Orange Book and FDA listings?
Answer: Identify suppliers by reconciling:
- the Orange Book entry tied to Belbuca’s NDA,
- the FDA drug establishment registration/listing entries for that NDA/drug product, and
- the labeling “Manufactured for/Distributed by” and manufacturing subsection.
Orange Book listing linkage
Orange Book identifies the NDA and patents (composition, method, formulation, exclusivity). It does not directly enumerate every CMO, but it anchors the correct NDA so you can query FDA establishment records for the same product.
FDA establishment and labeling linkage
FDA establishment registrations list drug manufacturing and packaging sites tied to specific dosage forms. The best operational approach is to:
- Use the product’s NDA and dosage form to pull the “manufacturing/packaging” establishment names.
- Map those to known CMO capabilities (film extrusion/coating, lamination, cutting/die formation, blister/strip packaging, carton packout).
Are there contract manufacturing organizations (CMOs) that supply BELBUCA?
Answer: Yes, Belbuca’s buccal film production typically involves specialized film fabrication, finishing, and packaging that is commonly handled by CMOs under the NDA holder’s quality agreements and FDA-approved manufacturing sections.
What CMO roles apply to buccal film supply?
- Film manufacturing: coating/lamination steps that produce buccal film uniformity.
- Cutting and forming: die-cutting or segmenting film into unit-dose strips.
- Primary packaging: foil pouches, trays, or strips depending on label format.
- Secondary packaging: cartons, labeling, and lot control.
How does this affect “supplier” due diligence?
A “supplier” in procurement should be treated as a specific FDA-approved site, not just a corporate entity. A corporate parent may contract with multiple sites; only some may be approved for the exact dosage form/strength.
What ingredients suppliers feed BELBUCA (buprenorphine) film manufacturing?
Answer: Active pharmaceutical ingredient (API) and excipient supply is controlled via:
- API source(s) referenced in regulatory filings for buprenorphine used in the film,
- excipient and film-former DMFs tied to the approved formulation, and
- GMP release testing and specifications for film components.
What inputs matter for buccal film supply chain?
- Buprenorphine substance (API)
- Film-forming polymer(s)
- Plasticizer and solubilizer components that enable buccal drug release
- Taste-masking or stabilizers used to meet acceptance criteria
- Packaging component suppliers (pouches, foil laminates, strip forming materials)
Why do ingredient suppliers matter for risk
Ingredient shortages or DMF supply disruptions can force manufacturing site switching. That can require manufacturing supplements or variation approvals depending on the change scope.
When does BELBUCA face supply disruptions or manufacturing constraints?
Answer: Supply disruption risk is generally tied to:
- single-site dependence for specific film strengths or packaging formats,
- DMF ingredient availability (film-former polymer or plasticizer),
- regulatory constraints on site transfers and process changes, and
- FDA inspection outcomes that can pause product release.
How to assess supply risk with supplier mapping
Use the labeled manufacturing sites for each strength:
- If a strength is made/packaged at fewer sites, it has higher outage risk.
- If multiple sites exist, check whether each site is approved for the same packaging configuration and labeling version.
Which suppliers supply BELBUCA to wholesalers and pharmacies?
Answer: Distribution typically routes through the NDA holder’s distribution network and contracted wholesalers, but the controllable supply for product availability is the GMP manufacturing and packaging sites. Wholesaler names change; establishment sites do not.
How procurement should model “supply”
Treat “supply” as two layers:
- GMP supply (approved sites that can make and package Belbuca film lots)
- Commercial distribution (wholesalers that can carry and deliver inventory)
How does BELBUCA compare with other buprenorphine buccal film brands on supplier structure?
Answer: Buprenorphine buccal films with similar dosage forms often share a similar supplier pattern: specialized film-former DMFs plus a small number of film-dedicated CMOs for cutting and unit-dose formation. Supplier structures can diverge based on whether film is in-house or contracted and whether each product uses distinct packaging formats.
What to compare in supplier due diligence
- Number of FDA-approved packaging sites
- Whether film cutting and finishing occur at the same site as coating
- Whether unit-dose strips are formed under a single packaging approval
Key tables: BELBUCA supplier mapping blueprint (what to populate for a procurement dossier)
Because supplier identification depends on FDA-specific establishment listings and labeling for the exact Belbuca strengths and package configuration, the actionable procurement artifact is a filled matrix tied to the NDA/drug product record.
Supplier matrix template (fill from FDA establishment records for Belbuca)
| Belbuca strength |
Role |
FDA-approved establishment name |
City/State |
Functions (make/pack/test) |
Corporate entity (if different) |
| Example: strength A |
Manufacturer |
[FDA establishment] |
[Location] |
Film fabrication |
[Entity] |
| Example: strength A |
Packager |
[FDA establishment] |
[Location] |
Unit-dose packaging |
[Entity] |
| Example: strength B |
Manufacturer |
[FDA establishment] |
[Location] |
Film fabrication |
[Entity] |
| Example: strength B |
Packager |
[FDA establishment] |
[Location] |
Strip/carton packaging |
[Entity] |
Key Takeaways
- “Supplier” for Belbuca should be mapped to FDA-approved manufacturing and packaging establishments tied to the product’s NDA and dosage form, not just corporate marketing entities.
- Belbuca’s buccal film format implies specialized film fabrication and finishing roles, which are frequently handled by CMOs under NDA holder control and FDA-approved processes.
- Ingredient and DMF supply (film-former, plasticizers, packaging components) drives manufacturing continuity and determines which sites can reliably produce and release inventory.
- Supplier risk analysis for Belbuca should be strength-specific because packaging and even film process approvals can differ by strength.
FAQs
1) What is the NDA number for BELBUCA buprenorphine buccal film?
Use the Orange Book Belbuca entry to identify the NDA number tied to the buccal film dosage form and specific strengths.
2) How can I verify BELBUCA manufacturers using FDA databases?
Cross-reference the Belbuca Orange Book NDA with FDA drug establishment registration and the product’s labeling “Manufactured for/Distributed by” entries.
3) Are BELBUCA packaging suppliers the same as film manufacturing suppliers?
Often not. Packaging can be performed at separate FDA-approved establishments from film fabrication and finishing.
4) Can BELBUCA be manufactured at multiple sites for all strengths?
Not necessarily. Some strengths and packaging configurations may be approved at different numbers of sites depending on validation history and submissions.
5) What supplier-related changes most affect BELBUCA supply continuity?
DMF-linked excipient or film component changes and site transfers that require approval can affect release timelines and short-term availability.
References
(No sources were provided in the prompt.)
